Trump meets Zelenskiy, says Putin wants war to end, mulls trilateral talks
NEW YORK - TG Therapeutics, Inc. (NASDAQ: TGTX), a biopharmaceutical company with an impressive market capitalization of $5.2 billion and strong year-over-year revenue growth of 33.5%, has presented new data on its multiple sclerosis drug BRIUMVI (ublituximab-xiiy) at the annual Consortium of Multiple Sclerosis Centers (CMSC) meeting. The presentations focused on the long-term treatment of relapsing forms of multiple sclerosis (RMS) with BRIUMVI, including safety, tolerability, and infusion reactions. According to InvestingPro analysis, the company maintains exceptional gross profit margins of 87.4%, indicating strong commercial potential for its drug portfolio.
The data presented came from several sources, including the ULTIMATE I & II Phase 3 trials and the ENHANCE Phase 3b study. These trials involved 1,094 RMS patients across 10 countries and were led by Dr. Lawrence Steinman of Stanford University. The studies compared BRIUMVI with teriflunomide, an active comparator, over a treatment period of 96 weeks.
One of the presentations, led by Dr. Bruce Cree from the University of California, San Francisco, indicated no association between decreases in serum immunoglobulin levels and serious infections in long-term treatment with BRIUMVI. Another presentation by Dr. Edward Fox of TG Therapeutics discussed the tolerability of the drug in a real-world observational survey. Additionally, Dr. John Foley from Rocky Mountain Multiple Sclerosis in Salt Lake City, Utah, presented updates on the safety and tolerability of 30-minute BRIUMVI infusions.
BRIUMVI is a monoclonal antibody that targets CD20-expressing B-cells and is designed for efficient B-cell depletion at low doses. It is approved for the treatment of adults with RMS, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.
The press release also highlighted the importance of monitoring for potential infusion reactions and infections in patients treated with BRIUMVI. It mentioned the need for screening for Hepatitis B Virus (HBV) before starting treatment and the absence of Progressive Multifocal Leukoencephalopathy (PML) in BRIUMVI-treated MS patients, despite its occurrence with other MS therapies.
TG Therapeutics is a biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has emphasized its commitment to supporting patients through their treatment journey with BRIUMVI. With a strong financial position reflected by a current ratio of 4.02 and analysts forecasting continued profitability, TG Therapeutics appears well-positioned for future growth. For detailed analysis and comprehensive insights, investors can access the full Pro Research Report available on InvestingPro, which provides expert analysis of the company’s financial health and growth prospects.
This article is based on a press release statement from TG Therapeutics, Inc.
In other recent news, TG Therapeutics reported its first-quarter 2025 financial results, highlighting a notable miss on earnings per share (EPS) but a slight beat on revenue expectations. The company’s EPS was $0.03, significantly below the forecasted $0.16, while revenue reached $119.7 million, surpassing the $117.13 million estimate and reflecting a 137% year-over-year growth. Despite the EPS shortfall, the company raised its full-year 2025 U.S. net revenue guidance to $560 million, indicating confidence in its ongoing market performance. Jefferies analyst Roger Song maintained a Buy rating on TG Therapeutics with a price target of $46.00, emphasizing the company’s financial positioning and operational strategy. The company reported a cash position of $276 million, which supports its commercial strategy and pipeline advancements. TG Therapeutics is also preparing for a direct-to-patient TV commercial campaign and continues to explore lifecycle improvements for its flagship product, BREONVY. The company anticipates maintaining a cash-neutral position throughout the year, despite increased R&D and SG&A expenses in the first quarter. Investors are closely monitoring TG Therapeutics’ progress, especially following the recent stock price decline after the earnings announcement.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.